Eyenovia, Inc.
https://eyenovia.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eyenovia, Inc.
Keeping Track: Recent NDA Submissions Range From Acute Agitation To Von Hippel-Lindau Disease
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
Deal Watch: RedHill Finds New Partner For Movantik
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Drug Delivery
- Site Specific
- Other Names / Subsidiaries
-
- PGP Holdings V, Inc.